Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

L.A. McKeown

April 24, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

New Scientific Statement Focuses on Below-the-Knee Technical Challenges

L.A. McKeown

January 19, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

L.A. McKeown

June 07, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

Top Endovascular News of 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

FDA Approves Bioresorbable Scaffold for BTK Lesions

New Scientific Statement Focuses on Below-the-Knee Technical Challenges

Top Endovascular News of 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Top Endovascular News of 2022

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

Lutonix BTK Studies: Below-the-Knee Challenges Linger

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content